Workflow
Teva Pharmaceutical Industries Limited - Special Call
TEVATEVA(US:TEVA) Seeking Alpha·2025-09-22 18:53

Core Points - The conference call is focused on the presentation of Phase III SOLARIS data for Olanzapine LAI TEV-'749, which is related to schizophrenia treatment [1][4] - The call includes forward-looking statements, and the company does not commit to updating these statements post-call [2] Company Overview - Teva has a strong neuroscience legacy, which is emphasized by the Executive VP of Global R&D and Chief Medical Officer during the call [4]